Therefore, this study aimed to evaluate the diagnostic utility of circulating levels of aggrecan, decorin, and biglycan as potential biomarkers of tissue destruction and/or indicators of therapeutic response in children with JIA treated with the biologic drug etanercept (ETA). The gene discussed is BGN; the disease is juvenile idiopathic arthritis.